NAUT
Nautilus Biotechnology, Inc.
$1.72
-0.01 (-0.58%)
At close · Jul 6
Market Cap
$218.58M
Shares
127,078,855
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.72
Open$1.75
Day$1.67–1.76
52W$0.62–4.31
Avg vol 30d809K
Short int541K · 0.4% float · 1.3d
Short vol55%
Last earningsApr 28, 2026
DataAug 2020–Jul 2026
Filing10-Q · Apr 28
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−20% below
−
Price vs 50-day avg
−30% below
◦
RSI (14)
29 · oversold
−
MACD trend
negative
◦
52-week position
30% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $2 — 50d above 200d
+
Institutional flow
+22% holders QoQ · +26 funds added
−
Insider flow
Net -$11.8M over 90 days · 100% sells
+
Short interest
0.43% of float · ▼ -28.8% MoM · 1.3 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
83 holders — mid 3-yr range
Fundamentals
Strong
+
EPS growth
+16% Y/Y
−
Free cash flow
$-52.0M
+
Balance sheet
net cash $12.4M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Jul 28, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 28, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−20% below
Bearish
Price vs 50-day avg
−30% below
Bearish
RSI (14)
29 · oversold
Neutral
MACD trend
negative
Bearish
52-week position
30% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+22% holders QoQ · +26 funds added
Insider flow
Distributing
Net -$11.8M over 90 days · 100% sells
Short interest
Falling
0.43% of float · ▼ -28.8% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
83 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 30%
52-wk high $4
vs 200-day avg -20%
vs 50-day avg -30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NAUT
this stock
Nautilus Biotechnology, Inc.
|
$218.58M | -11.8% | — | — | 0.4% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.92B | +16.8% | +46.2% | 31.1 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.87B | +9.0% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NAUT | -14.0% | -35.8% | -16.5% | -8.0% | -11.8% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -17.1% | -35.1% | -24.7% | -8.6% | -22.0% |